Amgen Decides To Discontinue Original List Price Option For Repatha

(RTTNews) - Amgen (AMGN) said Repatha will be distributed exclusively at the 60% lower list price of $5,850 per year, effective Dec. 31, 2019. The company also announced the discontinuation of the original list price option for Repatha. Amgen introduced the lower list priced option of Repatha in October 2018.

"We are discontinuing the original list price option so that payers and Medicare Part D health plans have clarity and can do their part: cover the lower list price option of Repatha to help every patient prescribed Repatha fill their prescription at an affordable, low fixed dollar co-pay," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More